Although these findings support the long-term benefits of aHCL therapy in subjects with T1DM, emerging evidence suggests that glycemic outcomes may be influenced by factors such as sex differences in insulin sensitivity, hormonal fluctuations, and behavioral aspects of diabetes management. Here, INS is linked to type 1 diabetes mellitus.